Pancreatic Cancer Research

ResearcherLyon 1 UniversitéActive in the last 2 years

Mickaël Lesurtel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2397-4599; OpenAlex author ID A5073802838. Sources: OpenAlex.

Their work

Papers
19 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
116
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 8 papers · 2026: 1 paper

Papers 19

  1. Laparoscopic left pancreatectomy is safe for the treatment of pancreatic ductal adenocarcinoma treated by chemoradiotherapy compared to open left pancreatectom… Co-author DOI 10.1007/s00464-026-12991-3↗
  2. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  3. Distal pancreatectomy with celiac axis resection (DP-CAR) for pancreatic ductal adenocarcinoma in a retrospective monocentric cohort: neoadjuvant treatment and… Co-author DOI 10.1016/j.hpb.2025.04.009↗
  4. Laparoscopic pancreatoduodenectomy is safe for the treatment of pancreatic ductal adenocarcinoma treated by chemoradiotherapy compared with open pancreatoduode… Co-author DOI 10.1016/j.surg.2024.09.041↗
  5. Laparoscopic compared with open pancreatoduodenectomy is safe for the treatment of pancreatic ductal adenocarcinoma treated by chemoradiotherapy. Co-author DOI 10.1016/j.surg.2025.109281↗
  6. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  7. Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PROD… Co-author DOI 10.1200/jco-24-01378↗
  8. Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter T… Co-author DOI 10.1245/s10434-024-16735-2↗
  9. Total Pancreatectomy for Locally Advanced Pancreatic Adenocarcinoma with Coeliac Trunk Resection and Retrograde Gastric Revascularization Through Aorto-Hepato-… Co-author DOI 10.1245/s10434-024-16844-y↗
  10. Distal Pancreatectomy for Body Pancreatic Ductal Adenocarcinoma: Is Splenectomy Necessary? A Propensity Score Matched Study. Co-author DOI 10.1245/s10434-024-15220-0↗
  11. Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study. Co-author DOI 10.1245/s10434-022-12387-2↗
  12. Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials. Co-author DOI 10.1097/sla.0000000000005126↗
  13. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. Co-author DOI 10.1001/jamaoncol.2020.3537↗
  14. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette s… Last author DOI 10.1186/s12885-019-5889-5↗
  15. Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Co-author DOI 10.1245/s10434-018-6391-z↗
  16. Correction to: Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. Co-author DOI 10.1245/s10434-018-6442-5↗
  17. [Pancreatic cancer- a curable disease]. Co-author DOI 10.1024/1661-8157/a001990↗
  18. Extended lymphadenectomy in patients with pancreatic cancer is debatable. Co-author DOI 10.1007/s00268-013-2064-z↗
  19. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III s… Co-author DOI 10.1186/1471-2407-11-346↗

Closest collaborators

The 25 strongest of 116 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alain Sauvanet Sauvanet · 9 shared papers, 2018–2026 · strength 1.90
  2. Safi Dokmak · 6 shared papers, 2024–2026 · strength 1.64
  3. Elias Karam · 3 shared papers, 2025–2026 · strength 0.89
  4. Louis de Mestier · 2 shared papers, 2025–2026 · strength 0.56
  5. Vinciane Rebours · 2 shared papers, 2025 · strength 0.51
  6. Olivia Hentic Dhome · 2 shared papers, 2025 · strength 0.51
  7. Jerome F. Cros · 2 shared papers, 2024–2025 · strength 0.45
  8. Marc G. Besselink · 5 shared papers, 2018–2025 · strength 0.42
  9. Frederik Christiaan Berrevoet · 5 shared papers, 2011–2025 · strength 0.35
  10. Marco Del Chiaro · 4 shared papers, 2018–2025 · strength 0.33
  11. Jorg H. Kleeff · 4 shared papers, 2018–2025 · strength 0.33
  12. Giuseppe Fusai · 4 shared papers, 2018–2025 · strength 0.33
  13. Knut Jørgen Labori · 4 shared papers, 2018–2025 · strength 0.33
  14. Roberto Salvia · 4 shared papers, 2018–2025 · strength 0.33
  15. Ana Vlasceanu · 1 shared paper, 2026 · strength 0.32
  16. Julien Touzmanian · 1 shared paper, 2025 · strength 0.30
  17. Maxime Ronot · 1 shared paper, 2025 · strength 0.25
  18. Thibaud Bertrand · 1 shared paper, 2025 · strength 0.25
  19. Morgan Bonds · 2 shared papers, 2020–2025 · strength 0.22
  20. Giuseppe Malleo · 2 shared papers, 2020–2025 · strength 0.22
  21. Alberto Balduzzi · 2 shared papers, 2020–2025 · strength 0.22
  22. Tobias Keck · 2 shared papers, 2020–2025 · strength 0.22
  23. Asif Halimi · 2 shared papers, 2020–2025 · strength 0.22
  24. Adnan A. Alseidi · 2 shared papers, 2020–2025 · strength 0.22
  25. Daniel Pietrasz · 2 shared papers, 2020–2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.